Cancer-Associated Thrombosis

For established cancer-associated VTE, select LMWH or a DOAC rather than a vitamin K antagonist when feasible. Both classes are supported for long-term treatment, whereas vitamin K antagonists add INR monitoring and interaction burden in patients receiving anticancer therapy. PubMed+2PubMedUpdate on Guidelines for the Management of Cancer‐Associated Thrombosis - PMCPubMedTreatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. - AbstractPubMedDOACs or VKAs or LMWH – What is the optimal regimen for cancer-associated venous thromboembolism? A systematic review and meta-analysis - PMC

A DOAC is reasonable when the patient can reliably take and absorb oral medication, has no major interacting anticancer or supportive-care drug, and does not have a tumor-associated mucosal bleeding concern. Apixaban, edoxaban, and rivaroxaban are identified options for long-term anticoagulation; in cancer-specific DOAC trials, transition from LMWH occurred when the next LMWH dose was due. Wiley+1WileyCancer‐associated thrombosis and drug–drug interactions of ...ASCOVenous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

Prefer LMWH when the clinical consequence of mucosal bleeding is high, particularly with gastrointestinal malignancy. Across active-cancer VTE studies, rivaroxaban, edoxaban, and LMWH had similar efficacy, but bleeding was more frequent with DOACs; gastrointestinal and genitourinary bleeding was higher with DOACs than with LMWH. ScienceDirect+1ScienceDirectTreatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulantsnice org ukRationale and impact | Venous thromboembolic diseases: diagnosis, management and thrombophilia testing | Guidance | NICE

When LMWH is selected, one cited dosing approach is 1 mg/kg subcutaneously every 12 hours; for creatinine clearance less than 30 mL/min, the cited summary lists 1 mg/kg once daily and advises avoiding LMWH in dialysis. Renal impairment should trigger reassessment of agent selection because both recurrent VTE and major bleeding were higher in patients with baseline glomerular filtration rate below 60 mL/min/1.73 m2 in the CLOT-related analysis. PubMed+1PubMedCancer-Associated Thrombosis - StatPearls - NCBI BookshelfASCOVenous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

Dalteparin has trial-based cancer-associated thrombosis dosing of 200 IU/kg subcutaneously daily for 1 month followed by 150 IU/kg daily for 5 months. Tinzaparin was studied at 175 IU/kg once daily for 6 months. These regimens establish therapeutic LMWH options but do not remove the need to tailor therapy to renal function and bleeding risk. ASCOASCOVenous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

Plan at least 6 months of therapeutic anticoagulation for cancer-associated VTE. At the 6-month review, do not stop automatically: ongoing active cancer and other persistent recurrence risks support continued therapy, whereas bleeding events, changing platelet counts, renal decline, and evolving treatment interactions may favor an agent change or discontinuation. Wiley+1WileyCancer‐associated thrombosis and drug–drug interactions of ...PubMedTreatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. - Abstract

For acute cancer-associated VTE with high recurrence risk and thrombocytopenia, consider platelet transfusion support to maintain platelet counts above 50,000/μL so therapeutic anticoagulation can continue. This approach prioritizes prevention of early thrombus progression or recurrence when thrombotic risk is high. Wiley+1WileyCancer‐associated venous thrombosis in adults (second edition)PubMedBest evidence summary on anticoagulant management in patients with cancer-associated venous thromboembolism

For platelet counts from 25,000 to 50,000/μL, individualize the decision according to clot burden, acuity, recurrence risk, current bleeding, and anticipated platelet recovery. A platelet count of at least 50,000/μL is identified as a threshold for pharmacologic prophylaxis; active bleeding, thrombocytopenia below 50,000/μL, hemorrhagic coagulopathy, or an indwelling neuraxial catheter are cited reasons to use mechanical rather than pharmacologic prophylaxis in hospitalized patients. PubMed+1PubMedBest evidence summary on anticoagulant management in patients with cancer-associated venous thromboembolismPubMedCancer-Associated Thrombosis - StatPearls - NCBI Bookshelf

Do not extrapolate prophylaxis thresholds to a stable therapeutic-treatment plan without assessing the acute VTE risk. In thrombocytopenic cancer-associated splanchnic vein thrombosis, both major bleeding and recurrent or progressive thrombosis were frequent, supporting case-specific selection rather than a uniform anticoagulant rule. ASHASHImpact of thrombocytopenia on bleeding and thrombotic outcomes in ...

When VTE recurs during anticoagulation, first establish that the event is new or progressive and review missed doses, incorrect dosing, changes in renal function, vomiting or malabsorption, and newly introduced interacting cancer therapies. These factors are particularly consequential with oral anticoagulants because cancer treatment commonly introduces drug-drug interaction and gastrointestinal tolerance problems. ScienceDirect+2ScienceDirectTreatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulantsScienceDirectTreating cancer-associated venous thromboembolism: A practical approachnice org ukRationale and impact | Venous thromboembolic diseases: diagnosis, management and thrombophilia testing | Guidance | NICE

For confirmed breakthrough VTE, practical options are to increase the LMWH dose by 20% to 25% or change to a DOAC; if recurrence occurs during a DOAC, switch to LMWH; and if recurrence occurs during a vitamin K antagonist, switch to LMWH or a DOAC. Select the new strategy after reassessing tumor-associated bleeding risk rather than simply escalating the current oral agent. PubMedPubMedBest evidence summary on anticoagulant management in patients with cancer-associated venous thromboembolism

Do not routinely place an IVC filter for recurrent VTE despite anticoagulation; the cited ASH recommendation suggests not using an IVC filter in this setting. A filter decision therefore requires a separate indication rather than recurrence alone. PubMedPubMedBest evidence summary on anticoagulant management in patients with cancer-associated venous thromboembolism

For hospitalized patients with cancer and acute medical illness, consider pharmacologic prophylaxis in the absence of contraindications; LMWH is the preferred agent in the cited guideline summary, with UFH or LMWH also identified in NCCN-based inpatient recommendations. Do not provide pharmacologic prophylaxis simply because a patient is admitted for chemotherapy or stem-cell transplantation without a qualifying risk profile. PubMed+1PubMedUpdate on Guidelines for the Management of Cancer‐Associated Thrombosis - PMCPubMedCancer-Associated Thrombosis - StatPearls - NCBI Bookshelf

Patients undergoing major cancer surgery should receive perioperative thromboprophylaxis unless contraindicated. Guidelines summarized here recommend beginning prophylaxis preoperatively and continuing for at least 7 to 10 days postoperatively. PubMedPubMedUpdate on Guidelines for the Management of Cancer‐Associated Thrombosis - PMC

For ambulatory patients receiving systemic chemotherapy, do not use routine prophylaxis for all patients. Consider LMWH or a DOAC for patients with high or intermediate VTE risk, including a Khorana Risk Score of 2 or higher, after screening for bleeding risk and interaction concerns. Wiley+1WileyAssociated</fc> Thrombosis - The OncologistPubMedDirect-Acting Oral Anticoagulant Therapy in Cancer Patients—A Review